Scientists identify gene that may contribute to improved rice yield

Public release date: 28-Sep-2008

Contact: Barbara K. Kennedy
science@psu.edu
814-863-4682
Penn State
Scientists identify gene that may contribute to improved rice yield
The researchers created transgenic lines of rice (G-2 and G-8) in which the GIF1 gene was overexpressed.

A team of scientists, including Penn State Distinguished Professor of Biology Hong Ma, has identified a gene in rice that controls the size and weight of rice grains. The gene may prove to be useful for breeding high-yield rice and, thus, may benefit the vast number of people who rely on this staple food for survival. "Our work shows that it is possible to increase rice's yield by enhancing the expression of a particular gene," said Ma. The team's results will be published on 28 September 2008 in an early online edition of the journal Nature Genetics, and in the November print issue of the journal.

The researchers first searched for and identified mutant strains of rice that exhibited underweight grains. "We found a particular mutant that is defective in its ability to produce normal-sized grains," said Zuhua He, a biology professor at the Chinese Academy of Sciences and the leader of the team. The group then examined the mutant and found that it carried a mutation within the GIF1 gene. "The GIF1 gene is responsible for controlling the activity of the enzyme invertase, which is located in the cell wall and converts sucrose to substances that then are used to create starch," said He. "Invertase is important in the formation of starch within developing grains of rice. If invertase is not active, the rice plant cannot produce edible grains."

Next, to test the ability of the GIF1 gene to control the production of invertase, the team measured the activity of invertase within a normal strain of rice, in which the GIF1 gene lacked any mutations, and within a mutant strain of rice, in which the GIF1 gene contained a mutation that caused a defect in the invertase activity. The scientists found that invertase activity in the mutant strain was only 17 percent of the activity that was observed in the normal strain, suggesting that the GIF1 gene does, indeed, control invertase activity. The team then created transgenic lines of rice in which the GIF1 gene is overexpressed and found that, compared with normal strains, the transgenic rice had larger and heavier grains.

According to Ma, the team was surprised to find that the GIF1 gene was so specialized in controlling invertase activity in a particular part of the grain -- the vascular tissue, which transports nutrients, including sugars generated by invertase, to the developing grain. "The expression pattern was not expected, in part, because invertase is a general enzyme that is used by many cell types. In fact, the corresponding gene in wild rice is not expressed specifically."

The team also found that the GIF1 gene is one of the genes that were selected during the domestication of rice. "By selectively growing only those strains of rice with heavier grains, humans for thousands of years unknowingly have been increasing the frequency of rice populations that had modifications in the GIF1 gene," said Ma. "This process has caused GIF1 to be expressed specifically in the vascular tissue and, thus, to produce larger rice grains," said Ma.

The scientists hope that their findings will help others to create hybrid varieties of rice that produce even larger grains. In the meantime, they plan to perform additional analyses that will help them to understand how other genes might be involved in the process of improving rice yield. "The goal is to understand what controls grain weight and other factors, and to look for ways to increase yield," said Ma.

###

This research was supported by grants from the Ministry of Science and Technology of China, the National Science Foundation of China, and the Shanghai Institutes for Biological Sciences.

[ Sara LaJeunesse ]

CONTACTS
Hong Ma: (+1) 814-863-6414, hxm16@psu.edu
Zuhua He: zhhe@sibs.ac.cn
Barbara Kennedy (PIO): (+1) 814-863-4682, science@psu.edu

IMAGE
A high-resolution image related to this story is on the Web at: http://www.science.psu.edu/alert/Ma9-2008.htm
After the embargo lifts, image captions and the text of this press release will be posted there, as well. For your convenience in preparing your stories in advance of the embargo date, the image caption is provided below:

CAPTION AND CREDIT FOR IMAGE:
The researchers created transgenic lines of rice (G-2 and G-8) in which the GIF1 gene was overexpressed. Compared to normal strains (WT), they found that the transgenic rice had larger and heavier grains. In this figure, the grains on the top are from white rice and the grains on the bottom are from brown rice.
Credit: Zuhua He, Chinese Academy of Sciences

Idaho National Laboratory researchers meet major hydrogen milestone

Idaho National Laboratory reports this week a notable achievement in hydrogen producing technology.

K.S.Parthasarathy




Public release date: 18-Sep-2008

Contact: Teri Ehresman
Teri.Ehresman@inl.gov
208-520-6252
DOE/Idaho National Laboratory
Idaho National Laboratory researchers meet major hydrogen milestone

A team of scientists from the U.S. Department of Energy's Idaho National Laboratory earlier this month reached a major milestone with the successful production of hydrogen through High-Temperature Electrolysis (HTE).

The milestone was reached when the Integrated Laboratory Scale experiment started producing hydrogen at a rate of 5.6 cubic meters per hour.

The achievement was recognized at a media event in Idaho Falls Sept. 18.

"This is by far the biggest achievement we've had," said Carl Stoots, the experiment's principal investigator.

High-Temperature Electrolysis is a system of producing hydrogen very efficiently by using technology originally developed for solid oxide fuel cells. HTE is a significant improvement over the more conventional methods to produce hydrogen. HTE uses an electric current through water to separate it into hydrogen and oxygen. Combined with a clean power source such as a next-generation nuclear plant, HTE could produce hydrogen at 45 to 55 percent efficiency.

There are several potential applications of hydrogen from high-temperature electrolysis, all of which are closer to being actualized now that HTE has proven itself capable of producing hydrogen at such an advanced level. Hydrogen is commonly used to help produce liquid fuels. INL Laboratory Fellow Steve Herring, who heads the HTE project, said it could also prove helpful in upgrading fuel from the Athabasca Tar Sands in Alberta, Canada, because producing gasoline and diesel fuel from such heavy oil deposits requires extensive amounts of hydrogen and steam.

September's achievement is a major scale-up from earlier INL experiments on a small scale. Herring said his team wanted it to match the final product closely.

With this milestone met, the HTE plant is on its way to opening many doors for innovation in energy production, contributing to the Department of Energy's overarching goal of a "hydrogen economy." Eventually, HTE could provide pure hydrogen for fuel cell-powered cars, Herring said – "but that's a long way off."

###

The HTE plant is located in the Bonneville County Technology Center, 101 Technology Drive in Idaho Falls, across the street from the INL Research Center.

Study shows pine bark naturally reduces knee osteoarthritis

Public release date: 3-Sep-2008

Contact: Melanie Nimrodi
mnimrodi@mww.com
312-546-3508



MWW Group
Study shows pine bark naturally reduces knee osteoarthritis
Third clinical trial reconfirms strong evidence pycnogenol lowers joint pain, symptoms; May now have lasting effect on joints following cessation of the extract

According to the Center for Disease Control (CDC), osteoarthritis, the most common type of arthritis, is on the rise. A new study published in the August journal of Phytotherapy Research, reveals Pycnogenol, bark extract from the French maritime pine tree, reduced overall knee osteoarthritis (OA) symptoms by 20.9 percent and lowered pain by 40.3 percent. To date, this is the third clinical trial on osteoarthritis treatment with Pycnogenol. This study investigated what happens to joint symptoms after treatment with Pycnogenol is terminated and the results show that no relapse occurred after two weeks. Pycnogenol acts as potent anti-inflammatory and the lasting effects found in this study suggest that Pycnogenol may help the joints to recover.

With osteoarthritis cases on the rise, many are seeking non-traditional medication to help ease the pain and reduce the amount of traditional medication taken. The CDC estimates osteoarthritis affects 34 percent of all adults over the age of 65. In 2005, an estimated 26.9 million adults in the U.S. had osteoarthritis, which was up from 21 million in 1990. While there's no known cure for osteoarthritis, treatments such as nonsteroidal anti-inflammatory drugs (NSAIDs) or analgesics can help reduce pain and also maintain joint movement, to help the quality of life for people living with the disease. In more severe cases, cortisone shots and joint replacement surgery are used to treat OA.

"The current study is in accordance with the two previous Pycnogenol studies for osteoarthritis," said Dr. Peter Rohdewald, one of the researchers of the study. "Again the pain is gradually decreasing during the course of three months treatment with Pycnogenol. An improvement is found after the first month and a further improvement is seen after two months, where values are significantly different to the placebo group. This study again showed that patients required significantly less analgesic medication while supplementing with Pycnogenol, whereas this was not the case with the placebo-treated control group."

The study was held at Slovakia's Comenius University School of Medicine. One hundred patients with stage I or II OA were included in the study and were randomly allocated to either a Pycnogenol or placebo group. Patients were supplemented with 150 mg Pycnogenol or placebo per day over a period of three months. They were allowed to continue taking their NSAID or analgesics prescribed before the study but had to record every pill taken. The established Western Ontario McMaster questionnaire for joint function was employed to rate the pain level, and obtain measures of joint stiffness and to what extent the arthritis affects participation in daily activities. Patients were investigated in two week intervals over the treatment period of three months and a final time two weeks after discontinuation of medication.

The overall score, summarizing pain, stiffness and daily activities, improved statistical significantly by 20.9 percent in the Pycnogenol group. Interestingly, the joint improvement achieved with Pycnogenol persisted after intake of Pycnogenol was discontinued for four weeks. The joint pain decreased by 40.3 percent after completion of the three months supplementation with Pycnogenol and two weeks later the pain was still 36.1 percent lower than at baseline. Furthermore, 38 percent of patients in the Pycnogenol group required less NSAID's or other analgesic medication for joint pain.

"The anti-inflammatory potency of Pycnogenol explains the success in lowering joint pain and stiffness for arthritic joints," said Rohdewald. "After three recent clinical studies on osteoarthritis, Pycnogenol continues to demonstrate its effectiveness for osteoarthritis symptoms making it a viable, natural and safe alternative for individuals. This is the first study that investigated whether a relapse of symptoms occurs after taking Pycnogenol is stopped. The results show a lasting effect after discontinuation which suggest the anti-inflammatory mechanisms of Pycnogenol has allowed the joints to recover."

In another study this year (also published in the journal of Phytotherapy Research), Pycnogenol was shown to reduce osteoarthritis symptoms by 56 percent. Moreover, patients required 58 percent less standard pain medication, which greatly improved the gastrointestinal complications resulting from the pain medication by 63 percent. Last year, a study on osteoarthritis carried out at the University of Arizona Tucson (published in Nutrition Research) discovered that Pycnogenol was effective for improving pain and joint function. After three months in the Pycnogenol group, there was a reduction of 43 percent in pain, 35 percent in stiffness and 52 percent in physical function subscales, respectively. The placebo group showed no significant scores throughout the entire study.

###

Horphag Research, the exclusive worldwide distributor of Pycnogenol has filed for several patents for Pycnogenol's application for COX-1 and COX-2 inhibition and treatment of osteoarthritis.

About Pycnogenol®

Pycnogenol® is a natural plant extract originating from the bark of the maritime pine that grows along the coast of southwest France and is found to contain a unique combination of procyanidins, bioflavonoids and organic acids, which offer extensive natural health benefits. The extract has been widely studied for the past 35 years and has more than 220 published studies and review articles ensuring safety and efficacy as an ingredient. Today, Pycnogenol® is available in more than 600 dietary supplements, multi-vitamins and health products worldwide. For more information, visit www.pycnogenol.com.

Natural Health Science Inc. (NHS), based in Hoboken, New Jersey, is the North American distributor for Pycnogenol® (pic-noj-en-all) brand French maritime pine bark extract on behalf of Horphag Research. Pycnogenol® is a registered trademark of Horphag Research Ltd., Guernsey, and its applications are protected by U.S. patents #5,720,956 / #6,372,266 and other international patents. NHS has the exclusive rights to market and sell Pycnogenol® in North America and benefits from more than 35 years of scientific research assuring the safety and efficacy of Pycnogenol® as a dietary supplement. For more information about Pycnogenol® visit our Web site at www.pycnogenol.com.